Focused On-demand Library for Lysophospholipid acyltransferase 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

1-acylglycerophosphate O-acyltransferase MBOAT2; 1-acylglycerophosphocholine O-acyltransferase MBOAT2; 1-acylglycerophosphoethanolamine MBOAT2 O-acyltransferase; Lysophosphatidic acid acyltransferase; Lysophosphatidylcholine acyltransferase; Lysophosphatidylcholine acyltransferase 4; Lysophosphatidylethanolamine acyltransferase; Membrane-bound O-acyltransferase domain-containing protein 2

Alternative UPACC:

Q6ZWT7; A9EDR2; Q8NCE7; Q96KY4


Lysophospholipid acyltransferase 2 (LPLAT 2), encoded by the gene with accession number Q6ZWT7, plays a crucial role in the phospholipid remodeling pathway, known as the Lands cycle. It catalyzes the transfer of acyl groups to lysophospholipids, predominantly affecting lysophosphatidylethanolamine and lysophosphatidic acid. This enzyme's preference for oleoyl-CoA as the acyl donor underscores its specificity in lipid metabolism.

Therapeutic significance:

Understanding the role of Lysophospholipid acyltransferase 2 could open doors to potential therapeutic strategies. Its involvement in the critical reacylation step of the Lands cycle highlights its potential as a target for modulating lipid composition in cell membranes, which could have implications in diseases where lipid metabolism is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.